Maes Danielle J, Alaqeel Motaz, Parry Michael, Botchu Rajesh, Sumathi Vaiyapuri, Jeys Lee M, Stevenson Jonathan D
The Royal Orthopaedic Hospital NHS Foundation Trust, Bristol Road South, Northfield, Birmingham, B31 2AP, UK.
The Royal Orthopaedic Hospital NHS Foundation Trust, Bristol Road South, Northfield, Birmingham, B31 2AP, UK; Department of Orthopedic Surgery, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Eur J Surg Oncol. 2023 Feb;49(2):345-352. doi: 10.1016/j.ejso.2022.08.017. Epub 2022 Aug 19.
Haemorrhagic soft-tissue sarcomas (HSTS) are characterised by aggressive local growth and highly metastatic behaviour. We aimed to describe oncological outcomes and prognostic factors.
Retrospective review including 64 patients treated with palliation (n = 7), with limb salvage surgery (LSS) (n = 9), with neoadjuvant radiotherapy (RT) + LSS (n = 12), with LSS + adjuvant RT (n = 30) or amputation (n = 6). Kaplan-Meier survival analysis estimated overall survival (OS), metastasis-free survival (MFS) and local recurrence-free survival (LRFS). After uni- and multivariate analysis, prognostic factors affecting OS, MFS and LRFS were identified.
Median age was 67 years (IQR 23 years) with median follow-up of 11 months (IQR 28 months). All cases were high grade. Eight (13%) had pulmonary metastases at presentation and another 40 (63%) developed metastases after median 9 months (IQR 19 months). Median OS was 12 months (IQR 38 months), and estimated OS after two-years was 15.9% and 52.9% for patients with and without metastatic disease at presentation, respectively. Improved OS was associated with negative resection margins (p = 0.031), RT (p = 0.045), neoadjuvant RT (versus adjuvant RT, p = 0.044) and amputation (versus LSS, p < 0.001). MFS was 35.1% after two-years. LR occurred in 18 of 51 (35.3%) patients with surgically treated localised disease. LRFS was 63.4% after two-years and significantly affected by a negative margin (p = 0.042) and RT (p = 0.001).
Haemorrhagic soft-tissue sarcomas should be excised, either with amputation or LSS with a clear resection margin. If LSS is attempted, neoadjuvant RT reduces the risk of tumour spillage and early LR, enhances the feasibility of achieving clear resection margins, and offers superior overall survival compared to adjuvant RT.
出血性软组织肉瘤(HSTS)的特点是局部侵袭性生长和高转移行为。我们旨在描述肿瘤学结局和预后因素。
回顾性分析64例患者,其中接受姑息治疗的有7例,接受保肢手术(LSS)的有9例,接受新辅助放疗(RT)+LSS的有12例,接受LSS+辅助RT的有30例,接受截肢手术的有6例。采用Kaplan-Meier生存分析评估总生存期(OS)、无转移生存期(MFS)和无局部复发生存期(LRFS)。经过单因素和多因素分析,确定了影响OS、MFS和LRFS的预后因素。
中位年龄为67岁(四分位间距23岁),中位随访时间为11个月(四分位间距28个月)。所有病例均为高级别。8例(13%)初诊时已有肺转移,另外40例(63%)在中位时间9个月(四分位间距19个月)后发生转移。中位OS为12个月(四分位间距38个月),初诊时有无转移疾病患者的两年估计OS分别为15.9%和52.9%。OS的改善与手术切缘阴性(p=0.031)、放疗(p=0.045)、新辅助放疗(与辅助放疗相比,p=0.044)和截肢(与LSS相比,p<0.001)相关。两年后的MFS为35.1%。51例接受手术治疗的局限性疾病患者中有18例(35.3%)发生局部复发。两年后的LRFS为63.4%,并受到切缘阴性(p=0.042)和放疗(p=0.001)的显著影响。
出血性软组织肉瘤应行切除手术,可选择截肢或具有清晰手术切缘的LSS。如果尝试进行LSS,新辅助放疗可降低肿瘤播散和早期局部复发的风险,提高获得清晰手术切缘的可行性,并且与辅助放疗相比,可提供更好的总生存期。